Genetic variation in Chlamydia trachomatis and their hosts: Impact on disease severity and tissue tropism

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1129-1146

  Abdelsamed, Hossam ^a   Peters, Jan ^a   Byrne, Gerald I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Chlamydia trachomatis; disease severity; gene polymorphisms; genetic variation; genital tract infections; tissue tropism

Indexed keywords

CT229 PROTEIN; CYTOTOXIN; INCA PROTEIN; INCD PROTEIN; INCG PROTEIN; MEMBRANE PROTEIN; SPHINGOLIPID; TRYPTOPHAN SYNTHASE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL INCLUSION; CELL MIGRATION; CHLAMYDIA TRACHOMATIS; DISEASE SEVERITY; ENVIRONMENTAL CHANGE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RECOMBINATION; GENETIC VARIABILITY; GENOTYPE; HOST; HUMAN; IMMUNE RESPONSE; LIPID TRANSPORT; MODULATION; NONHUMAN; OPERON; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SEROTYPE; TROPISM;

ANIMALS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DISEASE MODELS, ANIMAL; GENETIC VARIATION; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 84884143265     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.80     Document Type: Review

References (153)

1. Abdelrahman YM, Belland RJ. The chlamydial developmental cycle. FEMS Microbiol. Rev. 29(5), 949-959 (2005).
2. Mylonas I. Female genital Chlamydia trachomatis infection: where are we heading? Arch. Gynecol. Obstet. 285(5), 1271-1285 (2012).
3. WHO. WHO weekly epidemiological record. 87, 161-168 (2012).
4. Stephens RS, Myers G, Eppinger M, Bavoil PM. Divergence without difference: phylogenetics and taxonomy of Chlamydia resolved. FEMS Immunol. Med. Microbiol. 55(2), 115-119 (2009).
5. Schachter J. Chlamydia intracellular biology, pathogenesis, and immunity. Stephens R (Ed.). American Society for Microbiology, Washington, DC, USA 139-177 (1999).
6. Harris SR, Clarke IN, Seth-Smith HM et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat. Genet. 44(4), 413-419, S1 (2012).
7. Seth-Smith HM, Harris SR, Skilton RJ et al. Whole-genome sequences of Chlamydia trachomatis directly from clinical samples without culture. Genome Res. 23(5), 855-866 (2013).
8. Collingro A, Tischler P, Weinmaier T et al. Unity in variety-the pan-genome of the Chlamydiae. Mol. Biol. Evol. 28(12), 3253-3270 (2011).
9. Gottlieb SL, Martin DH, Xu F, Byrne GI, Brunham RC. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J. Infect. Dis. 201(Suppl. 2), S190-S204 (2010).
10. Atik B, Skwor TA, Kandel RP et al. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS ONE 3(10), e3600 (2008).
11. Conway DJ, Holland MJ, Campbell AE et al. HLA class I and II polymorphisms and trachomatous scarring in a Chlamydia trachomatis-endemic population. J. Infect. Dis. 174(3), 643-646 (1996).
12. Mozzato-Chamay N, Mahdi OS, Jallow O, Mabey DC, Bailey RL, Conway DJ. Polymorphisms in candidate genes and risk of scarring trachoma in a Chlamydia trachomatis-endemic population. J. Infect. Dis. 182(5), 1545-1548 (2000).
13. Natividad A, Cooke G, Holland MJ et al. A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC Med. Genet. 7, 40 (2006).
14. Natividad A, Hanchard N, Holland MJ et al. Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians. Genes Immun. 8(4), 288-295 (2007).
15. Natividad A, Holland MJ, Rockett KA et al. Susceptibility to sequelae of human ocular Chlamydial infection associated with allelic variation in IL10 cis-regulation. Hum. Mol. Genet. 17(2), 323-329 (2008).
16. Natividad A, Hull J, Luoni G et al. Innate immunity in ocular Chlamydia trachomatis infection: contribution of IL8 and CSF2 gene variants to risk of trachomatous scarring in Gambians. BMC Med. Genet. 10, 138 (2009).
17. Natividad A, Wilson J, Koch O et al. Risk of trachomatous scarring and trichiasis in Gambians varies with SNP haplotypes at the interferon-gamma and interleukin-10 loci. Genes Immun. 6(4), 332-340 (2005).
18. White AG, Bogh J, Leheny W et al. HLA antigens in Omanis with blinding trachoma: markers for disease susceptibility and resistance. Brit. J. Ophthalmol. 81(6), 431-434 (1997).
19. Abbas M, Bobo LD, Hsieh YH et al. Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers. Invest. Ophthalmol. Vis. Sci. 50(4), 1734-1738 (2009).
20. Intracellular Pathogens I: Chlamydiales. Tan M, Bavoil P (Eds). American Society for Microbiology, Washington, DC, USA (2012).
21. Vos M. Why do bacteria engage in homologous recombination? Trends Microbiol. 17(6), 226-232 (2009).
22. Didelot X, Maiden MC. Impact of recombination on bacterial evolution. Trends Microbiol. 18(7), 315-322 (2010).
23. Kinnunen AH, Surcel HM, Lehtinen M et al. HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis-related tubal factor infertility: a case-control study. Hum. Reprod. 17(8), 2073-2078 (2002).
24. Murillo LS, Land JA, Pleijster J, Bruggeman CA, Pena AS, Morre SA. Interleukin-1B (IL-1B) and interleukin-1 receptor antagonist (IL-1RN) gene polymorphisms are not associated with tubal pathology and Chlamydia trachomatis-related tubal factor subfertility. Hum. Reprod. 18(11), 2309-2314 (2003).
25. Ohman H, Bailey R, Natividad A et al. Effect of IL12A and IL12B polymorphisms on the risk of Chlamydia trachomatis-induced tubal factor infertility and disease severity. Hum. Reprod. 27(7), 2217-2223 (2012).
26. Ohman H, Tiitinen A, Halttunen M et al. IL-10 polymorphism and cell-mediated immune response to Chlamydia trachomatis. Genes Immun. 7(3), 243-249 (2006).
27. Ohman H, Tiitinen A, Halttunen M, Lehtinen M, Paavonen J, Surcel HM. Cytokine polymorphisms and severity of tubal damage in women with Chlamydia-associated infertility. J. Infect. Dis. 199(9), 1353-1359 (2009).
28. Ohman H, Tiitinen A, Halttunen M, Paavonen J, Surcel HM. Cytokine gene polymorphism and Chlamydia trachomatis-specific immune responses. Hum. Immunol. 72(3), 278-282 (2011).
29. Sziller I, Babula O, Hupuczi P et al. Mannose-binding lectin (MBL) codon 54 gene polymorphism protects against development of pre-eclampsia, HELLP syndrome and pre-eclampsia-associated intrauterine growth restriction. Mol. Hum. Reprod. 13(4), 281-285 (2007).
30. Tokuriki N, Stricher F, Serrano L, Tawfik DS. How protein stability and new functions trade off. PLoS Comput. Biol. 4(2), e1000002 (2008).
31. Dreiseikelmann B. Translocation of DNA across bacterial membranes. Microbiol. Rev. 58(3), 293-316 (1994).
32. Raes J, van De Peer Y. Gene duplication, the evolution of novel gene functions, and detecting functional divergence of duplicates in silico. Appl. Bioinformatics 2(2), 91-101 (2003).
33. Zhang J. Evolution by gene duplication: an update. Trends Ecol. Evol. 18(6), 292-298 (2003).
34. Serres MH, Kerr AR, Mccormack TJ, Riley M. Evolution by leaps: gene duplication in bacteria. Biol. Direct 4, 46 (2009).
35. Nunes A, Borrego MJ, Nunes B, Florindo C, Gomes JP. Evolutionary dynamics of ompA, the gene encoding the Chlamydia trachomatis key antigen. J. Bacteriol. 191(23), 7182-7192 (2009).
36. Voigt A, Schofl G, Saluz HP. The Chlamydia psittaci genome: a comparative analysis of intracellular pathogens. PLoS ONE 7(4), e35097 (2012).
37. Suchland RJ, Jeffrey BM, Sandoz KM, Stamm WE, Rockey DD. Generation of recombinant C. trachomatis strains for associating individual genes with known phenotypes. In: Proceedings of the 12th International Symposium on Human Chlamydial Infections. International Chlamydia Symposium, San Fransisco, CA, USA (2010).
38. Seth-Smith HM, Harris SR, Persson K et al. Co-evolution of genomes and plasmids within Chlamydia trachomatis and the emergence in Sweden of a new variant strain. BMC Genomics 10, 239 (2009).
39. Unemo M, Seth-Smith HM, Cutcliffe LT et al. The Swedish new variant of Chlamydia trachomatis: genome sequence, morphology, cell tropism and phenotypic characterization. Microbiology 156(Pt 5), 1394-1404 (2010).
40. Somboonna N, Wan R, Ojcius DM et al. Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages. MBio 2(3), e00045-11 (2011).
41. Jeffrey BM, Suchland RJ, Quinn KL, Davidson JR, Stamm WE, Rockey DD. Genome sequencing of recent clinical Chlamydia trachomatis strains identifies loci associated with tissue tropism and regions of apparent recombination. Infect. Immun. 78(6), 2544-2553 (2010).
42. Gomes JP, Bruno WJ, Nunes A et al. Evolution of Chlamydia trachomatis diversity occurs by widespread interstrain recombination involving hotspots. Genome Res. 17(1), 50-60 (2007).
43. Dean D, Stephens RS. Identification of individual genotypes of Chlamydia trachomatis from experimentally mixed serovars and mixed infections among trachoma patients. J. Clin. Microbiol. 32(6), 1506-1510 (1994).
44. Millman K, Black CM, Johnson RE et al. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J. Bacteriol. 186(8), 2457-2465 (2004).
45. Belland RJ, Scidmore MA, Crane DD et al. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc. Natl Acad. Sci. USA 98(24), 13984-13989 (2001).
46. Herrmann B. A new genetic variant of Chlamydia trachomatis. Sex Transm. Infect. 83(4), 253-254 (2007).
47. Ripa T, Nilsson P. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Euro. Surveill. 11(11), E061109.2 (2006).
48. Ripa T, Nilsson PA. A Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic acid amplification tests. Sex Transm. Dis. 34(5), 255-256 (2007).
49. Byrne GI. Chlamydia trachomatis strains and virulence: rethinking links to infection prevalence and disease severity. J. Infect. Dis. 201(Suppl. 2), S126-S133 (2010).
50. Jurstrand M, Falk L, Fredlund H et al. Characterization of Chlamydia trachomatis omp1 genotypes among sexually transmitted disease patients in Sweden. J. Clin. Microbiol. 39(11), 3915-3919 (2001).
51. Lysen M, Osterlund A, Rubin CJ, Persson T, Persson I, Herrmann B. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish county. J. Clin. Microbiol. 42(4), 1641-1647 (2004).
52. Millman KL, Tavare S, Dean D. Recombination in the ompA gene but not the omcB gene of Chlamydia contributes to serovar-specific differences in tissue tropism, immune surveillance, and persistence of the organism. J. Bacteriol. 183(20), 5997-6008 (2001).
53. Andreasen AA, Burton MJ, Holland MJ et al. Chlamydia trachomatis ompA variants in trachoma: what do they tell us? PLoS Negl. Trop. Dis. 2(9), e306 (2008).
54. Wang SP, Grayston JT. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am. J. Ophthalmol. 70(3), 367-374 (1970).
55. Brunelle BW, Sensabaugh GF. The ompA gene in Chlamydia trachomatis differs in phylogeny and rate of evolution from other regions of the genome. Infect. Immun. 74(1), 578-585 (2006).
56. Stothard DR, Boguslawski G, Jones RB. Phylogenetic analysis of the Chlamydia trachomatis major outer membrane protein and examination of potential pathogenic determinants. Infect. Immun. 66(8), 3618-3625 (1998).
57. Brunelle BW, Sensabaugh GF. Nucleotide and phylogenetic analyses of the Chlamydia trachomatis ompA gene indicates it is a hotspot for mutation. BMC Res. Notes 5, 53 (2012).
58. Dean D, Millman K. Molecular and mutation trends analyses of omp1 alleles for serovar E of Chlamydia trachomatis. Implications for the immunopathogenesis of disease. J. Clin. Invest. 99(3), 475-483 (1997).
59. Lee G, Park J, Kim B, Kim SA, Yoo CK, Seong WK. OmpA genotyping of Chlamydia trachomatis from Korean female sex workers. J. Infect. 52(6), 451-454 (2006).
60. Lister NA, Tabrizi SN, Fairley CK, Smith A, Janssen PH, Garland S. Variability of the Chlamydia trachomatis omp1 gene detected in samples from men tested in male-only saunas in Melbourne, Australia. J. Clin. Microbiol. 42(6), 2596-2601 (2004).
61. Mossman D, Beagley KW, Landay AL et al. Genotyping of urogenital Chlamydia trachomatis in regional New South Wales, Australia. Sex Transm. Dis. 35(6), 614-616 (2008).
62. Ngandjio A, Clerc M, Fonkoua MC et al. Screening of volunteer students in Yaounde (Cameroon, central Africa) for Chlamydia trachomatis infection and genotyping of isolated C. trachomatis strains. J. Clin. Microbiol. 41(9), 4404-4407 (2003).
63. Pedersen LN, Kjaer HO, Moller JK, Orntoft TF, Ostergaard L. High-resolution genotyping of Chlamydia trachomatis from recurrent urogenital infections. J. Clin. Microbiol. 38(8), 3068-3071 (2000).
64. Nunes A, Nogueira PJ, Borrego MJ, Gomes JP. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B-and T-cell epitopes: worldwide survey. PLoS ONE 5(10), e13171 (2010).
65. Galan JE, Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 284(5418), 1322-1328 (1999).
66. Peters J, Wilson DP, Myers G, Timms P, Bavoil PM. Type III secretion a la Chlamydia. Trends Microbiol. 15(6), 241-251 (2007).
67. Fields KA, Fischer ER, Mead DJ, Hackstadt T. Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J. Bacteriol. 187(18), 6466-6478 (2005).
68. Jorgensen I, Valdivia RH. Pmp-like proteins Pls1 and Pls2 are secreted into the lumen of the Chlamydia trachomatis inclusion. Infect. Immun. 76(9), 3940-3950 (2008).
69. Carabeo RA, Grieshaber SS, Fischer E, Hackstadt T. Chlamydia trachomatis induces remodeling of the actin cytoskeleton during attachment and entry into HeLa cells. Infect. Immun. 70(7), 3793-3803 (2002).
70. Clifton DR, Dooley CA, Grieshaber SS, Carabeo RA, Fields KA, Hackstadt T. Tyrosine phosphorylation of the chlamydial effector protein Tarp is species specific and not required for recruitment of actin. Infect. Immun. 73(7), 3860-3868 (2005).
71. Jiwani S, Alvarado S, Ohr RJ, Romero A, Nguyen B, Jewett TJ. Chlamydia trachomatis Tarp harbors distinct G and F actin binding domains which bundle actin filaments. J. Bacteriol. 195(4), 708-716 (2012).
72. Jewett TJ, Fischer ER, Mead DJ, Hackstadt T. Chlamydial Tarp is a bacterial nucleator of actin. Proc. Natl Acad. Sci. USA 103(42), 15599-15604 (2006).
73. Jewett TJ, Miller NJ, Dooley CA, Hackstadt T. The conserved Tarp actin binding domain is important for chlamydial invasion. PLoS Pathog. 6(7), e1000997 (2010).
74. Lutter EI, Bonner C, Holland MJ et al. Phylogenetic analysis of Chlamydia trachomatis Tarp and correlation with clinical phenotype. Infect. Immun. 78(9), 3678-3688 (2010).
75. Jewett TJ, Dooley CA, Mead DJ, Hackstadt T. Chlamydia trachomatis Tarp is phosphorylated by src family tyrosine kinases. Biochem. Biophys. Res. Commun. 371(2), 339-344 (2008).
76. Mehlitz A, Banhart S, Maurer AP et al. Tarp regulates early Chlamydia-induced host cell survival through interactions with the human adaptor protein SHC1. J. Cell Biol. 190(1), 143-157 (2010).
77. Almeida F, Borges V, Ferreira R, Borrego MJ, Gomes JP, Mota LJ. Polymorphisms in Inc proteins and differential expression of Inc genes among Chlamydia trachomatis strains correlate with invasiveness and tropism of lymphogranuloma venereum isolates. J. Bacteriol. 194(23), 6574-6585 (2012).
78. Lutter EI, Martens C, Hackstadt T. Evolution and conservation of predicted inclusion membrane proteins in Chlamydiae. Comp. Funct. Genomics 2012, 362104 (2012).
79. Dehoux P, Flores R, Dauga C, Zhong G, Subtil A. Multi-genome identification and characterization of Chlamydiae-specific type III secretion substrates: the Inc proteins. BMC Genomics 12, 109 (2011).
80. Li Z, Chen C, Chen D, Wu Y, Zhong Y, Zhong G. Characterization of fifty putative inclusion membrane proteins encoded in the Chlamydia trachomatis genome. Infect. Immun. 76(6), 2746-2757 (2008).
81. Mital J, Miller NJ, Fischer ER, Hackstadt T. Specific chlamydial inclusion membrane proteins associate with active Src family kinases in microdomains that interact with the host microtubule network. Cell Microbiol. 12(9), 1235-1249 (2010).
82. Spaeth KE, Chen YS, Valdivia RH. The Chlamydia type III secretion system C-ring engages a chaperone-effector protein complex. PLoS Pathog. 5(9), e1000579 (2009).
83. Clifton DR, Fields KA, Grieshaber SS et al. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc. Natl Acad. Sci. USA 101(27), 10166-10171 (2004).
84. Pannekoek Y, Spaargaren J, Langerak AA, Merks J, Morre SA, van Der Ende A. Interrelationship between polymorphisms of IncA, fusogenic properties of Chlamydia trachomatis strains, and clinical manifestations in patients in The Netherlands. J. Clin. Microbiol. 43(5), 2441-2443 (2005).
85. Rockey DD, Viratyosin W, Bannantine JP, Suchland RJ, Stamm WE. Diversity within inc genes of clinical Chlamydia trachomatis variant isolates that occupy non-fusogenic inclusions. Microbiology 148(Pt 8), 2497-2505 (2002).
86. Suchland RJ, Rockey DD, Bannantine JP, Stamm WE. Isolates of Chlamydia trachomatis that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane. Infect. Immun. 68(1), 360-367 (2000).
87. Geisler WM, Suchland RJ, Rockey DD, Stamm WE. Epidemiology and clinical manifestations of unique Chlamydia trachomatis isolates that occupy nonfusogenic inclusions. J. Infect. Dis. 184(7), 879-884 (2001).
88. Derre I, Swiss R, Agaisse H. The lipid transfer protein CERT interacts with the Chlamydia inclusion protein IncD and participates to ER-Chlamydia inclusion membrane contact sites. PLoS Pathog. 7(6), e1002092 (2011).
89. Borges V, Nunes A, Ferreira R, Borrego MJ, Gomes JP. Directional evolution of Chlamydia trachomatis towards niche-specific adaptation. J. Bacteriol. 194(22), 6143-6153 (2012).
90. Sugiki T, Takeuchi K, Yamaji T et al. Structural basis for the Golgi association by the pleckstrin homology domain of the ceramide trafficking protein (CERT). J. Biol. Chem. 287(40), 33706-33718 (2012).
91. Scidmore-Carlson MA, Shaw EI, Dooley CA, Fischer ER, Hackstadt T. Identification and characterization of a Chlamydia trachomatis early operon encoding four novel inclusion membrane proteins. Mol. Microbiol. 33(4), 753-765 (1999).
92. Scidmore MA, Hackstadt T. Mammalian 14-13-3b associates with the Chlamydia trachomatis inclusion membrane via its interaction with IncG. Mol. Microbiol. 39(6), 1638-1650 (2001).
93. Verbeke P, Welter-Stahl L, Ying S et al. Recruitment of BAD by the Chlamydia trachomatis vacuole correlates with host-cell survival. PLoS Pathog. 2(5), e45 (2006).
94. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat. Rev. Microbiol. 2(10), 802-808 (2004).
95. Belland RJ, Zhong G, Crane DD et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc. Natl Acad. Sci. USA 100(14), 8478-8483 (2003).
96. Shaw EI, Dooley CA, Fischer ER, Scidmore MA, Fields KA, Hackstadt T. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol. Microbiol. 37(4), 913-925 (2000).
97. Rzomp KA, Moorhead AR, Scidmore MA. The GTPase Rab4 interacts with Chlamydia trachomatis inclusion membrane protein CT229. Infect. Immun. 74(9), 5362-5373 (2006).
98. Grimwood J, Stephens RS. Computational analysis of the polymorphic membrane protein superfamily of Chlamydia trachomatis and Chlamydia pneumoniae. Microb. Comp. Genomics 4(3), 187-201 (1999).
99. Stephens RS, Kalman S, Lammel C et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282(5389), 754-759 (1998).
100. Henderson IR, Lam AC. Polymorphic proteins of Chlamydia spp.-autotransporters beyond the Proteobacteria. Trends Microbiol. 9(12), 573-578 (2001).
101. Gomes JP, Bruno WJ, Borrego MJ, Dean D. Recombination in the genome of Chlamydia trachomatis involving the polymorphic membrane protein C gene relative to ompA and evidence for horizontal gene transfer. J. Bacteriol. 186(13), 4295-4306 (2004).
102. Gomes JP, Nunes A, Bruno WJ, Borrego MJ, Florindo C, Dean D. Polymorphisms in the nine polymorphic membrane proteins of Chlamydia trachomatis across all serovars: evidence for serovar Da recombination and correlation with tissue tropism. J. Bacteriol. 188(1), 275-286 (2006).
103. Thalmann J, Janik K, May M et al. Actin re-organization induced by Chlamydia trachomatis serovar D-evidence for a critical role of the effector protein CT166 targeting Rac. PLoS ONE 5(3), e9887 (2010).
104. Carlson JH, Hughes S, Hogan D et al. Polymorphisms in the Chlamydia trachomatis cytotoxin locus associated with ocular and genital isolates. Infect. Immun. 72(12), 7063-7072 (2004).
105. Fehlner-Gardiner C, Roshick C, Carlson JH et al. Molecular basis defining human Chlamydia trachomatis tissue tropism. A possible role for tryptophan synthase. J. Biol. Chem. 277(30), 26893-26903 (2002).
106. Mojica S, Huot Creasy H, Daugherty S et al. Genome sequence of the obligate intracellular animal pathogen Chlamydia pecorum E58. J. Bacteriol. 193(14), 3690 (2011).
107. Read TD, Myers GS, Brunham RC et al. Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae. Nucleic Acids Res. 31(8), 2134-2147 (2003).
108. Thomson NR, Yeats C, Bell K et al. The Chlamydophila abortus genome sequence reveals an array of variable proteins that contribute to interspecies variation. Genome Res. 15(5), 629-640 (2005).
109. Xie G, Bonner CA, Jensen RA. Dynamic diversity of the tryptophan pathway in Chlamydiae: reductive evolution and a novel operon for tryptophan recapture. Genome Biol. 3(9), research0051 (2002).
110. Caldwell HD, Wood H, Crane D et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J. Clin. Invest. 111(11), 1757-1769 (2003).
111. Byrne GI, Lehmann LK, Landry GJ. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect. Immun. 53(2), 347-351 (1986).
112. Carlin JM, Borden EC, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J. Interferon Res. 9(3), 329-337 (1989).
113. Kane CD, Vena RM, Ouellette SP, Byrne GI. Intracellular tryptophan pool sizes may account for differences in gamma interferon-mediated inhibition and persistence of chlamydial growth in polarized and nonpolarized cells. Infect. Immun. 67(4), 1666-1671 (1999).
114. Leonhardt RM, Lee SJ, Kavathas PB, Cresswell P. Severe tryptophan starvation blocks onset of conventional persistence and reduces reactivation of Chlamydia trachomatis. Infect. Immun. 75(11), 5105-5117 (2007).
115. Rapoza PA, Tahija SG, Carlin JP, Miller SL, Padilla ML, Byrne GI. Effect of interferon on a primary conjunctival epithelial cell model of trachoma. Invest. Ophthalmol. Vis. Sci. 32(11), 2919-2923 (1991).
116. Dong Q, Brulc JM, Iovieno A et al. Diversity of bacteria at healthy human conjunctiva. Invest. Ophthalmol. Vis. Sci. 52(8), 5408-5413 (2011).
117. Zhou Y, Gao H, Mihindukulasuriya KA et al. Biogeography of the ecosystems of the healthy human body. Genome Biol. 14(1), R1 (2013).
118. Giles TN, Graham DE. Characterization of an acid-dependent arginine decarboxylase enzyme from Chlamydophila pneumoniae. J. Bacteriol. 189(20), 7376-7383 (2007).
119. Smith CB, Graham DE. Outer and inner membrane proteins compose an arginine-agmatine exchange system in Chlamydophila pneumoniae. J. Bacteriol. 190(22), 7431-7440 (2008).
120. Giles TN, Fisher DJ, Graham DE. Independent inactivation of arginine decarboxylase genes by nonsense and missense mutations led to pseudogene formation in Chlamydia trachomatis serovar L2 and D strains. BMC Evol. Biol. 9, 166 (2009).
121. Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J. Infect. Dis. 201(Suppl. 2), S114-S125 (2010).
122. Wang C, Tang J, Geisler WM, Crowley-Nowick PA, Wilson CM, Kaslow RA. Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents. J. Infect. Dis. 191(7), 1084-1092 (2005).
123. Conway DJ, Holland MJ, Bailey RL et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect. Immun. 65(3), 1003-1006 (1997).
124. Kari L, Whitmire WM, Olivares-Zavaleta N et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J. Exp. Med. 208(11), 2217-2223 (2011).
125. O'Connell CM, Ingalls RR, Andrews CW Jr, Scurlock AM, Darville T. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J. Immunol. 179(6), 4027-4034 (2007).
126. Bode J, Dutow P, Sommer K et al. A new role of the complement system: C3 provides protection in a mouse model of lung infection with intracellular Chlamydia psittaci. PLoS ONE 7(11), e50327 (2012).
127. Gondek DC, Roan NR, Starnbach MN. T cell responses in the absence of IFN-gamma exacerbate uterine infection with Chlamydia trachomatis. J. Immunol. 183(2), 1313-1319 (2009).
128. Imtiaz MT, Distelhorst JT, Schripsema JH et al. A role for matrix metalloproteinase-9 in pathogenesis of urogenital Chlamydia muridarum infection in mice. Microbes Infect. 9(14-15), 1561-1566 (2007).
129. Lee HY, Schripsema JH, Sigar IM et al. A role for CXC chemokine receptor-2 in the pathogenesis of urogenital Chlamydia muridarum infection in mice. FEMS Immunol. Med. Microbiol. 60(1), 49-56 (2010).
130. Olive AJ, Gondek DC, Starnbach MN. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 4(2), 208-216 (2011).
131. Pal S, Schmidt AP, Peterson EM, Wilson CL, de la Maza LM. Role of matrix metalloproteinase-7 in the modulation of a Chlamydia trachomatis infection. Immunology 117(2), 213-219 (2006).
132. Yang X, Brunham RC. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. J. Immunol. 161(3), 1439-1446 (1998).
133. Nagarajan UM, Prantner D, Sikes JD et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect. Immun. 76(10), 4642-4648 (2008).
134. Waterston RH, Lindblad-Toh K, Birney E et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915), 520-562 (2002).
135. Seok J, Warren HS, Cuenca AG et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110(9), 3507-3512 (2013).
136. Miyairi I, Tatireddigari VR, Mahdi OS et al. The p47 GTPases Iigp2 and Irgb10 regulate innate immunity and inflammation to murine Chlamydia psittaci infection. J. Immunol. 179(3), 1814-1824 (2007).
137. Miyairi I, Ziebarth J, Laxton JD et al. Host genetics and chlamydia disease: prediction and validation of disease severity mechanisms. PLoS ONE 7(3), e33781 (2012).
138. Bernstein-Hanley I, Balsara ZR, Ulmer W, Coers J, Starnbach MN, Dietrich WF. Genetic analysis of susceptibility to Chlamydia trachomatis in mouse. Genes Immun. 7(2), 122-129 (2006).
139. Bernstein-Hanley I, Coers J, Balsara ZR, Taylor GA, Starnbach MN, Dietrich WF. The p47 GTPases Igtp and Irgb10 map to the Chlamydia trachomatis susceptibility locus Ctrq-3 and mediate cellular resistance in mice. Proc. Natl Acad. Sci. USA 103(38), 14092-14097 (2006).
140. Nelson DE, Virok DP, Wood H et al. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl Acad. Sci. USA 102(30), 10658-10663 (2005).
141. Abdeltawab NF, Aziz RK, Kansal R et al. An unbiased systems genetics approach to mapping genetic loci modulating susceptibility to severe streptococcal sepsis. PLoS Pathog. 4(4), e1000042 (2008).
142. Boon AC, Debeauchamp J, Hollmann A et al. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J. Virol. 83(20), 10417-10426 (2009).
143. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 5(9), 1427-1442 (2010).
144. Schautteet K, de Clercq E, Miry C et al. Tetracycline-resistant Chlamydia suis in cases of reproductive failure on Belgian, Cypriote and Israeli pig production farms. J. Med. Microbiol. 62(Pt 2), 331-334 (2013).
145. Gaydos CA, Howell MR, Pare B et al. Chlamydia trachomatis infections in female military recruits. N. Engl. J. Med. 339(11), 739-744 (1998).
146. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW 3rd. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm. Dis. 35(2), 119-123 (2008).
147. Imai H, Nakao H, Shinohara H et al. Population-based study of asymptomatic infection with Chlamydia trachomatis among female and male students. Int. J. STD AIDS 21(5), 362-366 (2010).
148. CDC Grand Rounds. Chlamydia prevention: challenges and strategies for reducing disease burden and sequelae. MMWR Morb. Mortal. Wkly Rep. 60, 370-373 (2011).
149. Brunham RC, Rekart ML. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm. Dis. 35(1), 53-54 (2008).
150. Brunham RC, Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine 31(15), 1892-1897 (2013).
151. Brunham RC, Rekart M. Considerations on Chlamydia trachomatis disease expression. FEMS Immunol. Med. Microbiol. 55(2), 162-166 (2009).
152. Su W, Li Z, Li F, Chen X, Wan Q, Liang D. Doxycycline-mediated inhibition of corneal angiogenesis: an MMP-independent mechanism. Invest. Ophthalmol. Vis. Sci. 54(1), 783-788 (2013).
153. Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J. Infect. Dis. 199(9), 1379-1388 (2009).